PRQR - Why Shares of ProQR Therapeutics Dropped on Wednesday
2023-03-29 12:30:55 ET
Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. The biotech stock is up more than 174% over the past year, but down more than 32% so far in 2023.
ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-based therapies to treat rare genetic diseases, especially inherited eye diseases. ProQR released its fourth-quarter and full-year earnings before the market opened on Wednesday, along with an update regarding its pipeline.
The biggest reason for the decline was the update, showing that two of its programs appear to be a little slow getting out of the gate. The company said AX-0810, targeting cholestatic disorders that cause a buildup of bile acids in the liver and can lead to liver failure, and AX-1412, to lower the chance of cardiovascular disease, are not expected to enter clinical development until late 2024 or early 2025. The company has eight programs in its pipeline but none in late-stage trials.
For further details see:
Why Shares of ProQR Therapeutics Dropped on Wednesday